NMDA receptor antagonist formulation with reduced neurotoxicity

The present invention is directed to pharmaceutical compositions of effective amounts of NMDA receptor antagonists and preservative for the administration to a patient in need of effective analgesia and anesthesia. The compositions of the invention advantageously do not cause any significant neuroto...

Full description

Saved in:
Bibliographic Details
Main Authors Mermelstein, Fred H, Albin, Randi
Format Patent
LanguageEnglish
Published 25.09.2007
Online AccessGet full text

Cover

More Information
Summary:The present invention is directed to pharmaceutical compositions of effective amounts of NMDA receptor antagonists and preservative for the administration to a patient in need of effective analgesia and anesthesia. The compositions of the invention advantageously do not cause any significant neurotoxicity. The preferred NMDA receptor antagonist is ketamine. The preferred preservative is benzalkonium chloride.